Heron Therapeutics Stock Forecast, Price & News

+0.25 (+1.38 %)
(As of 04/22/2021 02:58 PM ET)
Today's Range
Now: $18.41
50-Day Range
MA: $16.60
52-Week Range
Now: $18.41
Volume13,410 shs
Average Volume1.02 million shs
Market Capitalization$1.68 billion
P/E RatioN/A
Dividend YieldN/A
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing HTX-011, an investigational, dual-acting, and fixed-dose combination of the local anesthetic bupivacaine with a low dose of the nonsteroidal anti-inflammatory drug meloxicam, which is in Phase III clinical trials for pain management; and HTX-034, which is in Phase Ib/II clinical trials for postoperative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.
Heron Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:HRTX
Year FoundedN/A



Sales & Book Value

Annual Sales$145.97 million
Book Value$4.48 per share


Net Income$-204,750,000.00
Net Margins-216.18%


Market Cap$1.68 billion
Next Earnings Date5/5/2021 (Estimated)


Heron Therapeutics (NASDAQ:HRTX) Trading Up 2.9%
April 20, 2021 |
HRTX Jun 2021 15.000 call
April 18, 2021 |
HRTX Sep 2021 11.000 put
April 18, 2021 |
Heron Therapeutics (NASDAQ:HRTX) Shares Gap Down to $17.27
April 9, 2021 |
HRTX Crosses Above Key Moving Average Level
April 6, 2021 |
March 21, 2021 |
HRTX Jan 2021 21.000 put
December 30, 2020 |
HRTX Jan 2021 23.000 call
December 30, 2020 |
HRTX Jan 2021 25.000 call
December 27, 2020 |
See More Headlines


Overall MarketRank

1.68 out of 5 stars

Medical Sector

302nd out of 2,024 stocks

Pharmaceutical Preparations Industry

135th out of 771 stocks

Analyst Opinion: 3.4Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
+0.25 (+1.38 %)
(As of 04/22/2021 02:58 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive HRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions

Is Heron Therapeutics a buy right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Heron Therapeutics stock.
View analyst ratings for Heron Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Heron Therapeutics?

Wall Street analysts have given Heron Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Heron Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Heron Therapeutics' next earnings date?

Heron Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Heron Therapeutics

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics, Inc. (NASDAQ:HRTX) issued its quarterly earnings results on Wednesday, February, 24th. The biotechnology company reported ($0.68) EPS for the quarter, missing the Zacks' consensus estimate of ($0.65) by $0.03. The biotechnology company had revenue of $20.61 million for the quarter, compared to the consensus estimate of $18.38 million. Heron Therapeutics had a negative trailing twelve-month return on equity of 65.06% and a negative net margin of 216.18%.
View Heron Therapeutics' earnings history

How has Heron Therapeutics' stock price been impacted by Coronavirus (COVID-19)?

Heron Therapeutics' stock was trading at $13.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HRTX stock has increased by 32.6% and is now trading at $18.08.
View which stocks have been most impacted by COVID-19

What price target have analysts set for HRTX?

5 equities research analysts have issued 1 year target prices for Heron Therapeutics' shares. Their forecasts range from $21.00 to $35.00. On average, they anticipate Heron Therapeutics' share price to reach $26.00 in the next twelve months. This suggests a possible upside of 43.8% from the stock's current price.
View analysts' price targets for Heron Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the following people:
  • Dr. Barry D. Quart, Chairman & CEO (Age 64, Pay $954.11k)
  • Mr. John W. Poyhonen, Pres & Chief Commercial Officer (Age 61, Pay $421.25k)
  • Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. & Director (Age 61, Pay $694.59k)
  • Mr. David L. Szekeres, Exec. VP & COO (Age 47)
  • Ms. Lisa Peraza, VP & Chief Accounting Officer (Age 45)
  • Mr. Sean T. Ristine, VP of HR (Age 51)
  • Dr. Thomas B. Ottoboni, Chief Scientific Officer and Sr. VP of Pharmaceutical & Translational Sciences (Age 62)
  • Mr. Michael E. Mathews, Sr. VP of Pain Franchise (Age 58)
  • Dr. Chris M. Storgard, Chief Medical Officer (Age 55)

Who are some of Heron Therapeutics' key competitors?

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Editas Medicine (EDIT), Immunomedics (IMMU), bluebird bio (BLUE), AT&T (T) and Amarin (AMRN).

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Private Asset Management Inc. (0.21%) and Congress Park Capital LLC (0.21%). Company insiders that own Heron Therapeutics stock include Barry D Quart, Craig A Johnson, David Leslie Szekeres, John Poyhonen, Kevin C Tang, Kimberly Manhard and Waage Christian.
View institutional ownership trends for Heron Therapeutics

Which major investors are selling Heron Therapeutics stock?

HRTX stock was sold by a variety of institutional investors in the last quarter, including Congress Park Capital LLC. Company insiders that have sold Heron Therapeutics company stock in the last year include Craig A Johnson, David Leslie Szekeres, Kimberly Manhard, and Waage Christian.
View insider buying and selling activity for Heron Therapeutics
or view top insider-selling stocks.

Which major investors are buying Heron Therapeutics stock?

HRTX stock was purchased by a variety of institutional investors in the last quarter, including Private Asset Management Inc.. Company insiders that have bought Heron Therapeutics stock in the last two years include Barry D Quart, John Poyhonen, Kevin C Tang, and Waage Christian.
View insider buying and selling activity for Heron Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Heron Therapeutics?

Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $18.08.

How much money does Heron Therapeutics make?

Heron Therapeutics has a market capitalization of $1.65 billion and generates $145.97 million in revenue each year. The biotechnology company earns $-204,750,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis.

How many employees does Heron Therapeutics have?

Heron Therapeutics employs 223 workers across the globe.

What is Heron Therapeutics' official website?

The official website for Heron Therapeutics is

Where are Heron Therapeutics' headquarters?

Heron Therapeutics is headquartered at 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121.

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]

This page was last updated on 4/22/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.